Breaking News
1 day ago
Vaibhavi M.

FDA and M-CERSI host a July 2026 workshop on pediatric SLE extrapolation strategies, signaling evolving expectations for sponsors in autoimmune indications.
Vaibhavi M.

Teva launches AHZANTIVE biosimilar in Europe, targeting ophthalmic biologics where manufacturing complexity has limited biosimilar competition.
Vaibhavi M.

Intas Pharma appoints Muthukumar Anbalagan as GM–NDDS, signalling a strategic push into complex formulations for regulated markets.
Vaibhavi M.

Finerenone's clinical profile may extend beyond diabetic CKD, with implications for sNDA strategy and commercial-scale manufacturing planning.
Vaibhavi M.
